High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfectious

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 165-175

  Jin, Xia ^a   Demoitie, Marie Ange ^a   Donahoe, Sean M ^a   Ogg, Graham S ^b   Bonhoeffer, Sebastian ^c   Kakimoto, William M ^a   Gillespie, Geraldine ^b   Moss, Paul A ^b   Dyer, Wayne ^g   Kurilla, Michael G ^d   Riddell, Stanley R ^e   Downie, Jean ^g   Sullivan, John S ^g   McMichael, Andrew J ^b   Workman, Cassy ^g   Nixon, Douglas F ^a,f  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA A ANTIGEN; VIRUS ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; SUPERINFECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HLA-A ANTIGENS; HUMANS; MALE; T-LYMPHOCYTES;

EID: 0033958541     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315201     Document Type: Article

References (53)

1. 1. Andiman WA, Eastman R, Martin K, et al. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS. Lancet 1985; 2:1390-3.
2. 2. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338: 969-73.
3. 3. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995; 332: 12-8.
4. 4. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 158:449-56.
5. 5. Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108:585-94.
6. 6. Davis MG, Kenney SC, Kamine J, Pagano JS, Huang ES. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. Proc Natl Acad Sci USA 1987; 84:8642-6.
7. 7. Kenney S, Kamine J, Markovitz D, Fenrick R, Pagano J. An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci USA 1988; 85:1652-6.
8. 8. Britt WJ, Alford CA. Cytomegalovirus. In: Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia: Lippincolt-Raven. 1996:2493-524.
9. 9. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldslone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68:6103-10.
10. 10. Greenough TC, Brettler DB, Somasundaran M, Panicali DL, Sullivan JL. Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo. J Infect Dis 1997; 176:118-25.
11. 11. Koup RA, Safril JT, Cao Y, et al. Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994; 68:4650-5.
12. 12. Ogg GS, Jin X. Bonhoeffe S, et al. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998; 279:2103-6.
13. 13. Rinaldo C, Huang XL, Fan Z, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T lymphocytes activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors. J Virol 1995; 69:5838-42.
14. 14. Rowland-Jones S. Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
15. 15. Cranage MP, Whatmore AM, Sharpe SA, et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997; 229:143-54.
16. 16. Gallimore A, Cranage M, Cook N, et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995; 1:1167-73.
17. 17. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999; 283: 857-60.
18. 18. Jin X, Bauer DE, Tutlleton SE, et al. Dramatic rise in plasma viremia after CD8+ T-cell depletion in SIV-infected macaques. J Exp Med 1999; 189: 991-8.
19. 19. Ariyoshi K, Cham F, Berry N, et al. HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS 1995; 9:555-9.
20. 20. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1-(HIV-1) specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein Barr virus in late disease. J Exp Med 1993; 177:249-56.
21. 21. Kersten MJ. Klein MR. Holwerda AM, Miedema F, van Oers MH. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma. J Clin Invest 1997; 99:1525-33.
22. 22. Phillips RE, Rowland-Jones S, Nixon DF, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991; 354:453-9.
23. 23. Price DA, Goulder PJ, Klenerman P, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997; 94(5):1890-5.
24. 24. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31.
25. 25. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13:545-86.
26. 26. Quinnan GV Jr., Kirmani N, Rook AH, et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1982; 307:7-13.
27. 27. Borysiewicz LK, Hickling JK, Graham S, et al. Human cytomegalovirus-specific cytotoxic T cells: relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 1988; 168:919-31.
28. 28. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998; 8:89-95.
29. 29. Valitutti S, Muller S, Cella M, Padovan E, Lanzavecchia A. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature 1995; 375:148-51.
30. 30. Dubey C, Croft M, Swain SL. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J Immunol 1996; 157:3280-9.
31. 31. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 1990; 346: 574-6.
32. 32. Moskophidis D, Lechner F, Pircher H. Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993; 362:758-61.
33. 33. Sagerstrom CG, Kerr EM, Allison JP, Davis MM. Activation and differentiation requirements of primary T cells in vitro. Proc Natl Acad Sci USA 1993; 90:8987-91.
34. 34. Selin LK, Vergilis K, Welsh RM, Nahill SR. Reduction of otherwise remarkably stable virus-specific cytotoxic T lymphocyte memory by heterologous viral infections. J Exp Med 1996; 183:2489-99.
35. 35. Geretti AM, Dings MEM, van Els CACM, van Baalen CA, Wijnholds FJ, Osterhaus ADME. Human immunodeficiency virus type I (HIV-1)-and Epstein-Barr virus-specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1 infected persons. J Inf Dis 1996; 174:34-5.
36. 36. Klein MR, van Baalen CA, Holwerda AM, et al. Kinetics of gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics, J Exp Med 1995; 181:1365-72.
37. 37. Cao Y, Krogstad P, Korber BT, et al. Maternal HIV-1 viral load and vertical transmission of infection: the Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3:549-52.
38. 38. Borysiewicz LK, Graham S, Hickling JK, Mason PD, Sissons JG. Human cytomegalovirus-specific cytotoxic T cells: their precursor frequency and stage specificity. Eur J Immunol 1988; 18:269-75.
39. 39. Altman JD, Moss PAH, Goulder PJR, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6.
40. 40. Devore J, Peck R. Statistics: the exploration and analysis of data. 2d ed. Belmont, CA: Duxbury Press, 1993:733-53, 786-8.
41. 41. Markowitz M. Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type I infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179:527-37.
42. 42. Callan MF, Steven N, Krausa P, et al. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med 1996; 2:906-11.
43. 43. Gallant J, Moore R, Richman D, Keruly J, Chaisson R. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166(6):1223-7.
44. 44. Walter E, Greenberg P, Gilbert M, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333(16):1038-44.
45. 45. Butz EA, Bevan MJ. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 1998; 8:167-75.
46. 46. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997; 185:1605-17.
47. 47. Callan MF, Tan L, Annels N, et al. Direct visualisation of antigen specific CD8+ T cells during primary immune response to Epstein Barr virus in vivo. J Exp Med 1998; 187:1395-402.
48. 48. Sixbey J, Nedrud J, Raab-Traub N, Hanes R, Pagano J. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984; 310(19): 1225-30.
49. 49. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996; 70:7569-79.
50. 50. Young L, Clark D, Sixbey J, Rickinson A. Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet 1986; 1(8475):240-2.
51. 51. Taylor-Wiedeman J, Sissons J, Borysiewicz L, Sinclair J. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991; 72:2059-64.
52. 52. Taylor-Wiedeman J, Sissons P, Sinclair J. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol 1994; 68:1597-604.
53. 53. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-53.